New review says spinal decompression evidence may be misread

A peer-reviewed review by orthopedic spine surgeon Dr. Anuj Gupta argues that newer spinal decompression technologies should not be judged by old traction studies alone. The paper, published in Cureus, says device design, treatment dose and patient selection may change how the evidence should be interpreted.

Why it matters: - A new review argues that spinal decompression technologies may have been judged using evidence from older traction methods that do not match modern devices or protocols. - The distinction could affect how clinicians evaluate treatment options for disc-related back and neck pain. - The review says a more precise framework is needed for researchers, clinicians and patients weighing non-surgical spine care.

What happened: - Orthopedic spine surgeon Dr. Anuj Gupta published a peer-reviewed review in Cureus in May 2024. - The paper, “Evolving Spinal Treatment Modalities: A Review of the Literature on Non-surgical Interferential Differential Dynamics (IDD) Therapy,” examines the evolution of traction-based treatment into controlled non-surgical spinal decompression. - The review focuses on IDD Therapy® and the ACCU-SPINA® System, manufactured by North American Medical Corporation. - Gupta argues that newer decompression technologies should be evaluated on their own biomechanics, delivery methods and patient populations.

The details: - Traditional traction uses longitudinal pulling forces to separate spinal structures. - Modern spinal decompression technologies may use controlled force progression, level-specific positioning, distraction and relaxation cycles, and oscillatory movement. - Gupta describes spinal decompression as an evolution of traction rather than an entirely separate concept. - The review cautions against applying conclusions from older traction studies across different technologies, protocols and patient groups. - One 2009 randomized clinical trial often cited in discussions of IDD Therapy compared a standard protocol with a lower-force protocol described as sham. - Both groups in that trial were treated on the same decompression system and both received decompressive forces. - The full-treatment group progressed to approximately half body weight plus 10 pounds. - The sham group received 10 pounds. - Both groups improved in low-back pain, leg pain, functional outcomes and quality of life. - The trial did not find a statistically significant difference between groups. - Gupta says that trial should not be read as “treatment” versus “placebo.” - The review says lower-dose mechanical loading may still create a biological effect, including changes in pressure gradients and fluid exchange. - That makes control design a challenge in spinal-decompression research when the control itself may produce a mechanical effect. - The review says IDD Therapy on the ACCU-SPINA® System uses controlled distraction and relaxation cycles, level-specific positioning and sinusoidal oscillation. - Gupta discusses possible biomechanical effects on disc pressure, fluid exchange and paraspinal muscle activity. - Protective muscle contraction or guarding may reduce the effect of distraction, making delivery method clinically relevant. - The review also raises treatment dosage as a key issue. - Not every study labeled as spinal decompression research has used the same number of sessions, force levels or protocols. - Gupta notes that underdosing may limit therapeutic effect and alter outcomes. - The review says studies with fewer sessions than recommended have reported suboptimal outcomes. - Gupta says spinal decompression is not appropriate for every patient with back pain. - The review says patient selection matters because back pain can come from many structures and causes. - Gupta states in the review that IDD Therapy has a role in disc-related back pain in selected patients. - The paper concludes that IDD Therapy is an evolution of traction involving controlled decompressive forces and calls for larger, long-term studies.

Between the lines: - The review is less a defense of spinal decompression as a cure-all than a critique of how evidence is categorized. - The core argument is that “traction” is too broad a label when technologies differ in force delivery, oscillation, positioning and dose. - The 2009 trial is used as an example of how a weak control condition can blur the line between a sham and an active treatment. - That framing could matter for future studies because physical therapies can be harder to blind than drug trials.

What's next: - Gupta calls for larger, long-term studies on IDD Therapy and related decompression technologies. - Future research will likely need to define the exact technology, force delivery, session count and patient group being studied. - The review says those details should be treated as essential variables, not background noise. - North American Medical Corporation is based in Marietta, Georgia, and develops medical technologies for non-surgical spine and musculoskeletal care, including the ACCU-SPINA® System. - Media contact listed in the release is Gidgette Rubin, Senior Vice President, at Rubin@NAMcorporation.com and 770-541-0012 ext. 5333.